Loading...
XJPX
4564
Market cap50mUSD
Oct 09, Last price  
19.00JPY
1D
-5.00%
1Q
-5.00%
Jan 2017
-92.94%
IPO
-95.96%
Name

OncoTherapy Science Inc

Chart & performance

D1W1MN
XJPX:4564 chart
P/E
—
P/S
9.37
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.23%
Rev. gr., 5y
19.45%
Revenues
809m
+7.80%
804,491,0001,972,835,0003,327,575,0005,257,628,0005,361,397,0006,223,947,0003,277,411,0001,017,769,000769,956,000266,903,000286,667,000211,251,000280,586,000316,215,000332,477,0001,153,663,0001,134,903,000610,118,000750,048,000808,530,000
Net income
-911m
L+11.70%
-1,323,362,000-202,073,000148,249,000510,159,000566,758,000726,961,000-1,103,203,000-3,676,647,000-1,334,890,000-2,788,819,000-3,002,063,000-2,851,092,000-2,934,960,000-2,238,558,000-1,561,636,000-2,571,541,000-1,118,644,000-1,288,138,000-815,285,000-910,638,000
CFO
-923m
L+13.22%
-1,091,497,000346,225,000-223,504,0001,024,616,000440,961,000-91,325,000-455,654,000-1,649,667,000-1,702,607,000-2,898,286,000-2,988,040,000-3,035,947,000-2,373,427,000-2,275,529,000-1,762,629,000-2,073,224,000-794,901,000-1,227,990,000-815,021,000-922,751,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.

Key people

Jaehyun Park
President, Chief Executive Officer, Chief Scientific Officer, President of Subsidiary, Representative Director · since 2019
Hatsuo Kato
Chairman of the Board · since 2020
Junichi Shimada
Director · since 2022
Toyomasa Katagiri
Independent Director · since 2010
Yuichi Komine
Independent Director · since 2014
Yoshio Miki
Independent Director · since 2022
URL
https://www.oncotherapy.co.jp/
IPO date
Dec 08, 2003
Employees
60
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
川崎区東田町１番地２
川崎市, 14 210-0005
JP
Other language
OncoTherapy Science, Inc.

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT